Stock Taper
SCREENER COMPARE ANY 2 STOCKS
FENC
FENNEC PHARMACEUTICALS INC.
NASDAQ
$12.27
▲ UP 4.25% (0.50)

KEY STATISTICS

Market Cap$426.22 M
52w High$13.25
52w Low$5.65
Dividend Yield—
Frequency—
P/E-94.38
Volume421.65K
Shares Out.34.74M

COMPANY

LEADERSHIP

Jeffrey S. Hackman
CHIEF EXECUTIVE
Jeffrey S. Hackman

COMPENSATION 2026

Salary$586,343
Stock Awards$887,100
Incentive Plan Pay$0
All Other Comp.$0
Total$1,722,154

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 15, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
35

PRICE TARGET

Target High$16.00
Target Low$16.00
Target Median$16.00
Target Consensus$16.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$19.21M
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2014-09-09Reverse1:3
2011-08-31Reverse1:18
2005-08-02Reverse1:5

PRICE

$12.27 ▲ UP 4.25% (+$0.50)
OVERLAYS
$11.75$12.00$12.25$12.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM12.27

About Fennec Pharmaceuticals Inc.

https://www.fennecpharma.com ↗

Fennec Pharmaceuticals Inc., based in Research Triangle Park, NC, is a biopharmaceutical company developing PEDMARK, a sodium thiosulfate formulation to prevent platinum-induced hearing loss in pediatric cancer patients.

INDUSTRY

Biotechnology

A PRODUCT FENNEC PHARMACEUTICALS INC. IS KNOWN FOR

PEDMARK® (sodium thiosulfate injection)
PEDMARK® (sodium thiosulfate injection)

PEDMARK® (PEDMARQSI® in Europe/UK) is the FDA-approved prescription medicine that reduces hearing loss risk in children receiving cisplatin chemotherapy, addressing a critical unmet need in pediatric cancer treatment.

COMPETITORS

COMPETITOR
ACTU COMPARE
HRTX COMPARE

Revenue by Products

IconPRODUCTQ2-2026
Manufactured Product Other$18.89M
Service Other$710K

ETFS HOLDING THIS STOCK

ETFS HOLDING
19
LISTED HERE
5
RANKED BY POSITION SIZE
VTS.AX
0.00% · 815.2K
XSU.TO
0.01% · 743.7K
RSSL
0.01% · 13.8K
PQ
PQSG
0.21% · 4.2K
URTY
0.00% · 1.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
67.94%
HOLDERS
142
TOP 12 OF 142 · RANKED BY POSITION SIZE
Southpoint Capital Advisors LP
4.1M sh · $38.16M
Rosalind Advisors, Inc.
3.2M sh · $34.27M
Solas Capital Management, LLC
2.6M sh · $19.72M
Aigh Capital Management LLC
2.5M sh · $26.72M
Sonic Gp LLC
2.4M sh · $15.21M
Sonic Fund Ii, L.P.
2.4M sh · $19.5M
Blackrock, Inc.
1.7M sh · $18.57M
Blackrock Inc.
1.2M sh · $7.25M
Awm Investment Company, Inc.
1.2M sh · $12.47M
Vanguard Group Inc
1.1M sh · $8.22M
Kam Lawrence
834.7K sh · $5.42M
Prospect Capital Advisors, LLC
497.8K sh · $5.35M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Andrade Robert
Sale · 21.9K shares
2026-08-28
★
OFFICER: CHIEF FINANCIAL OFFICER
Andrade Robert
Purchase · 21.9K shares
2026-08-28
★
OFFICER: CHIEF FINANCIAL OFFICER
Andrade Robert
Sale · 75.0K shares
2026-08-27
★
OTHER: FORMER DIRECTOR
Raykov Rosty
Sale · 10.0K shares
2026-08-03

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OUTPERFORM 1
3 GRADES IN THE LAST 12 MONTHS
B. Riley Securities BUY Wedbush OUTPERFORM HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
AVTX$19.59COMPARE
PRLD$5.47COMPARE
ENTA$13.60COMPARE
OBIO$5.18COMPARE
RNAC$9.60COMPARE
EPRX$6.67COMPARE
CRBU$1.62COMPARE
BDTX$2.23COMPARE